Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from d...
Saved in:
| Published in | BMC medicine Vol. 5; no. 1; p. 20 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
19.07.2007
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1741-7015 1741-7015 |
| DOI | 10.1186/1741-7015-5-20 |
Cover
| Abstract | Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease.
We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease.
We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects > or =65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700,000 subjects taking simvastatin and over 50,000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p < 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p < 0.0001).
Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance. |
|---|---|
| AbstractList | BACKGROUND: Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease. METHODS: We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease. RESULTS: We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects ≥65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700000 subjects taking simvastatin and over 50000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p < 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p < 0.0001). CONCLUSION: Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance. Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease. We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease. We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects > or =65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700,000 subjects taking simvastatin and over 50,000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p < 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p < 0.0001). Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance. Abstract Background Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease. Methods We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease. Results We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects ≥65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700000 subjects taking simvastatin and over 50000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44–0.48, p < 0.0001) and 0.91 (CI 0.80–1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4–0.55, p < 0.0001). Conclusion Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance. Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease.BACKGROUNDStatins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease.We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease.METHODSWe analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease.We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects > or =65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700,000 subjects taking simvastatin and over 50,000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p < 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p < 0.0001).RESULTSWe observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects > or =65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700,000 subjects taking simvastatin and over 50,000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p < 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p < 0.0001).Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance.CONCLUSIONSimvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance. Background Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease. Methods We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease. Results We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects greater than or equal to 65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700000 subjects taking simvastatin and over 50000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p & 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p & 0.0001). Conclusion Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance. |
| ArticleNumber | 20 |
| Audience | Academic |
| Author | Wolozin, Benjamin Lee, Austin Wang, Stanley W Kazis, Lewis E Lee, Todd A Li, Nien-Chen |
| AuthorAffiliation | 1 Boston University School of Medicine, Boston, MA, USA 5 College of Science, Sungkyunkwan University, South Korea 2 Center for the Assessment of Pharmaceutical Practices (CAPP), Boston University School of Public Health, Boston, MA, USA 3 Center for Health Quality Outcomes and Economic Research (CHQOER) Veterans Administration Medical Center (VAMC), Bedford, MA, USA 6 Midwest Center for Health Services and Policy Research, Hines Veterans Affairs Medical Center, IL, USA 4 College of Management, National Cheng Kung University, Taiwan |
| AuthorAffiliation_xml | – name: 6 Midwest Center for Health Services and Policy Research, Hines Veterans Affairs Medical Center, IL, USA – name: 4 College of Management, National Cheng Kung University, Taiwan – name: 1 Boston University School of Medicine, Boston, MA, USA – name: 3 Center for Health Quality Outcomes and Economic Research (CHQOER) Veterans Administration Medical Center (VAMC), Bedford, MA, USA – name: 2 Center for the Assessment of Pharmaceutical Practices (CAPP), Boston University School of Public Health, Boston, MA, USA – name: 5 College of Science, Sungkyunkwan University, South Korea |
| Author_xml | – sequence: 1 givenname: Benjamin surname: Wolozin fullname: Wolozin, Benjamin – sequence: 2 givenname: Stanley W surname: Wang fullname: Wang, Stanley W – sequence: 3 givenname: Nien-Chen surname: Li fullname: Li, Nien-Chen – sequence: 4 givenname: Austin surname: Lee fullname: Lee, Austin – sequence: 5 givenname: Todd A surname: Lee fullname: Lee, Todd A – sequence: 6 givenname: Lewis E surname: Kazis fullname: Kazis, Lewis E |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17640385$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkstv1DAQhyNURB9w5YhyglOKHT_ivSCtKh6VKoHE42pN7MnulMQucVLEf4-3W9pdUIV8sD3-zTeex3FxEGLAonjO2SnnRr_mjeRVw7iqVFWzR8XRneFg53xYHKd0yVitmkY-KQ55oyUTRh0V3z7TcA1pgolCSamElKIjmNCXP2lal1CO6GeXrxQceQwOy9iVHgcME0EJwZefYPxOIcXwKpWeEkLCp8XjDvqEz273k-Lru7dfzj5UFx_fn58tL6pWczFVCKLj3InOMfBe-7wZQN1KAbxVoKHruloDk41sFh5Mg62SyqHAhTKKozgpzrdcH-HSXo00wPjLRiB7Y4jjysI4kevRCmVQMY_MeJeT161WxivHmeEtgofMerNlXc3tgN7lBEfo96D7L4HWdhWvLV8oJaXOgOUW0FJ8ALD_4uJgNz2ymx5ZZWuWGS9vPzHGHzOmyQ6UHPY9BIxzstrUXNTG_FeYWboWSmTh6Va4glwFCl3MsV1euYfk8jR1lO1Lrg3nktc75BuHNUI_rVPs54liSPvCF7sFu0v0z3Tdh3ZjTGnE7l7C7GZ8_81e_uXgaDOacVMv6h9y-w21BPOH |
| CitedBy_id | crossref_primary_10_3233_BPL_180078 crossref_primary_10_1016_j_atherosclerosis_2013_07_009 crossref_primary_10_1016_j_freeradbiomed_2016_10_008 crossref_primary_10_1016_j_jacl_2020_10_007 crossref_primary_10_1016_j_arr_2022_101723 crossref_primary_10_1111_cns_14888 crossref_primary_10_1007_s10787_023_01400_z crossref_primary_10_3389_fnmol_2017_00063 crossref_primary_10_1111_j_1471_4159_2010_06912_x crossref_primary_10_1517_14740330902859956 crossref_primary_10_1007_s00415_009_5271_7 crossref_primary_10_1007_s00249_007_0235_2 crossref_primary_10_1021_acschemneuro_3c00119 crossref_primary_10_1038_s41392_022_01125_5 crossref_primary_10_1016_j_pneurobio_2009_02_002 crossref_primary_10_2174_1874609812666190917155400 crossref_primary_10_1007_s11886_014_0559_3 crossref_primary_10_3389_fnagi_2018_00020 crossref_primary_10_1016_j_nbd_2013_09_018 crossref_primary_10_1097_MD_0000000000011304 crossref_primary_10_1016_j_neurobiolaging_2011_10_020 crossref_primary_10_1111_ene_12430 crossref_primary_10_1159_000480401 crossref_primary_10_1371_journal_pone_0175054 crossref_primary_10_1212_WNL_0000000000004818 crossref_primary_10_3389_fnmol_2018_00165 crossref_primary_10_3390_ijms17060904 crossref_primary_10_1007_s11908_012_0277_1 crossref_primary_10_1016_j_taap_2018_03_005 crossref_primary_10_1186_s12944_020_01284_w crossref_primary_10_1002_mds_22721 crossref_primary_10_1042_BST0390910 crossref_primary_10_1111_joim_12838 crossref_primary_10_1016_j_exger_2010_02_001 crossref_primary_10_3390_jpm12050825 crossref_primary_10_1080_03602532_2019_1687511 crossref_primary_10_1038_s41419_023_05977_9 crossref_primary_10_1080_17460441_2017_1271321 crossref_primary_10_1377_hlthaff_2013_1276 crossref_primary_10_3892_mmr_2017_8098 crossref_primary_10_1089_neu_2010_1624 crossref_primary_10_37376_ljst_v14i2_7205 crossref_primary_10_1016_j_ejphar_2022_174800 crossref_primary_10_2337_dcS15_3022 crossref_primary_10_1097_MD_0000000000014852 crossref_primary_10_1007_s12031_015_0666_7 crossref_primary_10_1016_j_expneurol_2010_12_014 crossref_primary_10_1007_s11936_016_0448_8 crossref_primary_10_3390_cells8010027 crossref_primary_10_1080_03602532_2016_1277737 crossref_primary_10_1080_22201009_2012_10872272 crossref_primary_10_1016_j_tcm_2016_03_009 crossref_primary_10_1038_pr_2013_152 crossref_primary_10_1186_s13195_020_00589_3 crossref_primary_10_1089_neu_2017_5545 crossref_primary_10_1038_ncpneuro0621 crossref_primary_10_4103_0019_5545_44900 crossref_primary_10_1016_j_mehy_2020_109602 crossref_primary_10_1371_journal_pone_0229541 crossref_primary_10_1021_jm500629e crossref_primary_10_1016_S1474_4422_16_30230_7 crossref_primary_10_1208_s12248_017_0176_3 crossref_primary_10_1016_j_jalz_2008_02_001 crossref_primary_10_2119_2007_00100_Irvine crossref_primary_10_4236_jss_2019_75010 crossref_primary_10_1016_S1261_694X_10_70108_5 crossref_primary_10_1093_gerona_glz135 crossref_primary_10_1016_j_brainres_2009_12_032 crossref_primary_10_1097_MD_0000000000016405 crossref_primary_10_1097_MLR_0b013e318268aaff crossref_primary_10_1016_j_neuroimage_2009_07_025 crossref_primary_10_1007_s10072_020_04243_6 crossref_primary_10_1146_annurev_cellbio_042308_113313 crossref_primary_10_3233_JPD_212819 crossref_primary_10_1016_j_expneurol_2010_04_006 crossref_primary_10_1021_ja303930f crossref_primary_10_1039_D2MO00267A crossref_primary_10_1515_revneuro_2023_0005 crossref_primary_10_1523_JNEUROSCI_4144_09_2009 crossref_primary_10_1016_j_pnpbp_2022_110637 crossref_primary_10_1016_j_jns_2008_06_022 crossref_primary_10_1016_j_pneurobio_2015_06_004 crossref_primary_10_3390_ijms17111809 crossref_primary_10_1002_ana_24751 crossref_primary_10_1073_pnas_1324209111 crossref_primary_10_1007_s00406_013_0468_2 crossref_primary_10_1186_1755_8794_2_2 crossref_primary_10_1007_s11920_009_0082_1 crossref_primary_10_1016_j_jmgm_2023_108498 crossref_primary_10_3109_00207454_2014_979288 crossref_primary_10_1007_s10072_024_07803_2 crossref_primary_10_1016_j_brainres_2012_06_050 crossref_primary_10_3233_JPD_171113 crossref_primary_10_1016_j_ccr_2012_02_025 crossref_primary_10_1080_14737175_2021_2003705 crossref_primary_10_1016_j_parkreldis_2018_05_013 crossref_primary_10_3390_ijms232415876 crossref_primary_10_3109_00207454_2012_704455 crossref_primary_10_1016_j_expneurol_2010_11_013 crossref_primary_10_1016_j_jff_2024_106034 crossref_primary_10_1002_gps_1910 crossref_primary_10_3233_JPD_171203 crossref_primary_10_12968_npre_2007_5_9_27413 crossref_primary_10_1016_j_lfs_2016_05_005 crossref_primary_10_1111_j_1750_3639_2009_00369_x crossref_primary_10_1007_s12031_016_0811_y crossref_primary_10_1007_s11011_017_0021_5 crossref_primary_10_4010_jln_18_51 crossref_primary_10_1097_NEN_0b013e31819ac3cb crossref_primary_10_1212_WNL_0000000000010433 crossref_primary_10_1016_j_jalz_2012_07_005 crossref_primary_10_4236_iim_2015_75022 crossref_primary_10_1007_s12010_013_0400_2 crossref_primary_10_1051_ocl_2018027 crossref_primary_10_1093_geronb_gbx147 crossref_primary_10_1016_j_mayocp_2013_07_013 crossref_primary_10_1093_cvr_cvac020 crossref_primary_10_1371_journal_pone_0088434 crossref_primary_10_3389_fphar_2025_1473796 crossref_primary_10_1038_s41531_017_0015_3 crossref_primary_10_1002_syn_21881 crossref_primary_10_1212_WNL_0b013e31829d873c crossref_primary_10_1093_europace_eux031 crossref_primary_10_1016_j_pharmthera_2022_108171 crossref_primary_10_1155_2013_814390 crossref_primary_10_3390_ijms20030719 crossref_primary_10_1097_NEN_0b013e318212f185 crossref_primary_10_3945_ajcn_114_098467 crossref_primary_10_1093_eurjpc_zwab208 crossref_primary_10_3389_fnins_2024_1422912 crossref_primary_10_14283_jarlife_2023_8 crossref_primary_10_3390_microorganisms12061133 crossref_primary_10_1007_s00221_011_2975_6 crossref_primary_10_1016_j_phrs_2012_12_002 crossref_primary_10_1111_j_1471_4159_2008_05254_x crossref_primary_10_3390_ijms231911550 crossref_primary_10_1016_S0929_6646_09_60402_2 crossref_primary_10_2165_0002018_200831120_00007 crossref_primary_10_3390_ijms20205090 crossref_primary_10_1007_s00702_011_0680_z crossref_primary_10_1002_ana_24813 crossref_primary_10_1007_s11055_019_00746_8 crossref_primary_10_1007_s13760_024_02709_4 crossref_primary_10_1016_j_ejphar_2009_03_026 crossref_primary_10_1007_s12035_014_8749_y crossref_primary_10_1007_s13530_024_00238_4 crossref_primary_10_3389_fphar_2014_00047 crossref_primary_10_4103_0019_5545_43631 crossref_primary_10_1002_biof_37 crossref_primary_10_1016_j_bbadis_2008_09_009 crossref_primary_10_1016_j_saa_2021_120045 crossref_primary_10_1177_0891988714522702 crossref_primary_10_1111_cts_12740 crossref_primary_10_1016_j_neuropharm_2018_01_039 crossref_primary_10_1371_journal_pcbi_1002503 crossref_primary_10_3390_biomedicines8020030 crossref_primary_10_1016_j_neulet_2015_08_054 crossref_primary_10_1038_nrneurol_2014_226 crossref_primary_10_1517_14728214_13_2_255 crossref_primary_10_1155_2012_179318 crossref_primary_10_1002_syn_21980 crossref_primary_10_3389_fpsyt_2023_1195028 crossref_primary_10_1016_j_metabol_2024_155794 crossref_primary_10_1007_s11883_014_0466_5 crossref_primary_10_2217_14796708_3_4_367 crossref_primary_10_1002_prp2_1063 crossref_primary_10_1080_17460441_2020_1746266 crossref_primary_10_1097_HCR_0b013e31825d2a03 crossref_primary_10_1371_journal_pone_0052755 crossref_primary_10_1186_s13024_019_0329_1 crossref_primary_10_1016_j_cca_2017_07_029 crossref_primary_10_1016_j_eplepsyres_2023_107282 crossref_primary_10_1586_ern_09_25 crossref_primary_10_3390_biomedicines8060145 crossref_primary_10_1016_j_pharmthera_2012_07_008 crossref_primary_10_1212_WNL_0000000000001814 crossref_primary_10_1007_s00115_014_4252_y crossref_primary_10_1002_mds_26152 crossref_primary_10_1038_mp_2014_81 crossref_primary_10_1248_bpb_b17_00641 crossref_primary_10_1038_s41598_022_07064_z crossref_primary_10_1002_mds_27006 crossref_primary_10_1007_s42250_022_00508_z crossref_primary_10_2119_molmed_2008_00118 crossref_primary_10_1007_s00415_012_6606_3 crossref_primary_10_1097_JGP_0b013e3181812790 crossref_primary_10_1007_s11596_015_1522_2 crossref_primary_10_3390_ijms151120607 crossref_primary_10_1016_j_neuroscience_2009_12_062 crossref_primary_10_3390_ijms20143531 crossref_primary_10_1002_jnr_23115 crossref_primary_10_1016_j_neurobiolaging_2014_03_037 crossref_primary_10_1177_1073858410385006 crossref_primary_10_3389_fnagi_2020_590546 crossref_primary_10_3724_SP_J_1008_2011_00092 crossref_primary_10_1371_journal_pone_0152564 crossref_primary_10_1111_j_1471_4159_2009_06408_x crossref_primary_10_1007_s12272_019_01131_2 crossref_primary_10_1071_MA17031 crossref_primary_10_1017_S0317167100015547 crossref_primary_10_3389_fchem_2014_00050 crossref_primary_10_2174_1570159X15666170703101816 crossref_primary_10_3233_JPD_212655 crossref_primary_10_1007_s13311_020_00853_2 crossref_primary_10_1016_j_neurobiolaging_2018_01_012 crossref_primary_10_1002_mds_23102 crossref_primary_10_1155_2023_9296092 crossref_primary_10_1002_pds_1485 crossref_primary_10_1111_epi_13924 crossref_primary_10_1002_pds_4079 crossref_primary_10_1093_aje_kwac054 crossref_primary_10_1111_j_1365_2125_2008_03308_x crossref_primary_10_1002_mds_22013 crossref_primary_10_1007_s13311_019_00731_6 crossref_primary_10_1016_j_biopha_2024_116376 crossref_primary_10_1016_j_mehy_2010_02_023 crossref_primary_10_1039_b807980n crossref_primary_10_1071_MA21021 crossref_primary_10_1177_0884533610373932 crossref_primary_10_1016_j_nbd_2019_104671 crossref_primary_10_1038_nrn3012 crossref_primary_10_1016_j_fct_2015_02_016 crossref_primary_10_4061_2011_250970 crossref_primary_10_1016_j_bcab_2017_11_002 crossref_primary_10_17116_jnevro2017117623_10 crossref_primary_10_1080_1028415X_2017_1376928 crossref_primary_10_1016_j_molmed_2010_07_008 crossref_primary_10_1212_01_wnl_0000341271_90478_8e crossref_primary_10_1016_j_ejphar_2017_07_018 crossref_primary_10_1007_s12035_012_8337_y crossref_primary_10_2217_clp_10_46 crossref_primary_10_1016_j_mcn_2009_07_013 crossref_primary_10_1016_j_neuroscience_2024_12_059 crossref_primary_10_1002_mds_27609 crossref_primary_10_1016_j_neuroimage_2007_12_066 crossref_primary_10_1007_s13311_013_0218_1 crossref_primary_10_1016_j_bbadis_2013_03_016 crossref_primary_10_1071_MA21034 crossref_primary_10_1074_jbc_M110_102277 crossref_primary_10_3233_JAD_240388 crossref_primary_10_1016_j_exger_2008_05_004 crossref_primary_10_1002_gps_2604 crossref_primary_10_1002_jcp_25488 crossref_primary_10_1007_s10571_012_9872_9 crossref_primary_10_1212_WNL_0b013e3181d6476a crossref_primary_10_15252_embr_201439225 crossref_primary_10_1002_mds_29349 crossref_primary_10_1016_j_trci_2019_07_012 crossref_primary_10_1371_journal_pone_0285529 crossref_primary_10_1038_nrneurol_2015_35 crossref_primary_10_4236_jss_2018_66003 crossref_primary_10_1016_j_tem_2019_02_003 crossref_primary_10_1016_j_jneuroim_2024_578364 crossref_primary_10_1021_acschemneuro_8b00456 crossref_primary_10_1039_c0mb00282h crossref_primary_10_1016_j_neuint_2015_07_025 crossref_primary_10_1097_WCO_0b013e3283050461 crossref_primary_10_1002_ana_24809 crossref_primary_10_1016_j_tins_2011_06_005 crossref_primary_10_1038_s41598_018_24248_8 crossref_primary_10_3233_JAD_180288 crossref_primary_10_1007_s12035_020_02232_6 crossref_primary_10_1016_j_pharmthera_2012_08_010 crossref_primary_10_1371_journal_pone_0220254 crossref_primary_10_1016_j_atherosclerosis_2013_07_055 crossref_primary_10_1016_j_bbr_2016_04_046 crossref_primary_10_1371_journal_pmed_1002265 crossref_primary_10_1371_journal_pone_0038144 |
| Cites_doi | 10.1212/01.wnl.0000172914.08967.dc 10.1016/S0140-6736(02)09327-3 10.1001/archinte.162.18.2046 10.1161/01.ATV.0000157145.98200.55 10.1111/j.1600-0404.2006.00687.x 10.1002/j.1552-4604.1997.tb04327.x 10.1001/archinte.165.17.2007 10.1016/S0140-6736(00)03155-X 10.1016/j.amjcard.2005.12.007 10.1001/archneur.62.5.753 10.1016/j.ahj.2005.04.003 10.1002/ana.10292 10.1016/S0002-8703(00)90033-4 10.1097/00043798-200306000-00004 10.1016/S1474-4422(05)70141-1 10.1001/archneur.59.3.378 10.1016/j.mad.2005.09.020 10.1007/s11906-004-0025-5 10.1161/01.CIR.0000091404.09558.AF 10.1016/S0140-6736(02)11600-X 10.1186/1478-7954-4-7 10.1016/j.amjhyper.2005.02.013 10.1016/j.amjcard.2005.12.031 10.1136/bmj.308.6944.1604 10.1159/000095679 10.1001/archneur.63.5.noc60013 10.1016/0895-4356(92)90133-8 10.1159/000087345 10.1124/pr.57.2.4 10.1111/j.1532-5415.2005.53360.x 10.1001/jama.283.24.3211 10.1001/archinte.162.4.405 10.1001/archneur.59.2.223 10.1001/archpsyc.62.2.217 10.1016/S0149-2918(03)80162-5 10.1177/1077558703256726 10.1016/j.amjcard.2004.02.006 10.1023/A:1018975928974 10.1016/S0002-9149(01)02337-2 10.1001/archneur.57.10.1439 10.1001/archneur.62.7.1047 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2007 BioMed Central Ltd. Copyright © 2007 Wolozin et al; licensee BioMed Central Ltd. 2007 Wolozin et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2007 BioMed Central Ltd. – notice: Copyright © 2007 Wolozin et al; licensee BioMed Central Ltd. 2007 Wolozin et al; licensee BioMed Central Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 7X8 5PM DOA |
| DOI | 10.1186/1741-7015-5-20 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Neurosciences Abstracts |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1741-7015 |
| EndPage | 20 |
| ExternalDocumentID | oai_doaj_org_article_358e50de08dc4036b658d5c1081beada PMC1955446 oai_biomedcentral_com_1741_7015_5_20 A168114128 17640385 10_1186_1741_7015_5_20 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- 0R~ 23N 2VQ 2WC 4.4 53G 5GY 5VS 6J9 6PF AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BFQNJ BMC C1A C6C CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P GROUPED_DOAJ GX1 H13 HYE IAO IHR IHW INH INR IPNFZ ITC KQ8 M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PQQKQ RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS WOQ WOW XSB CGR CUY CVF ECM EIF NPM 7TK 7X8 -5E -5G -A0 -BR ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 5PM |
| ID | FETCH-LOGICAL-b613t-ea3f11c3fc0add6dc0a8ae6b43a1b5a6afff26a047479da87eb545ce3e95851e3 |
| IEDL.DBID | M48 |
| ISSN | 1741-7015 |
| IngestDate | Wed Aug 27 01:30:31 EDT 2025 Thu Aug 21 13:50:43 EDT 2025 Wed May 22 07:12:59 EDT 2024 Fri Sep 05 09:27:13 EDT 2025 Thu Sep 04 23:04:43 EDT 2025 Tue Jun 10 21:25:41 EDT 2025 Thu May 22 20:58:08 EDT 2025 Mon Jul 21 05:31:54 EDT 2025 Thu Apr 24 23:06:00 EDT 2025 Tue Jul 01 01:14:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | http://www.springer.com/tdm This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b613t-ea3f11c3fc0add6dc0a8ae6b43a1b5a6afff26a047479da87eb545ce3e95851e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/1741-7015-5-20 |
| PMID | 17640385 |
| PQID | 20362353 |
| PQPubID | 23462 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_358e50de08dc4036b658d5c1081beada pubmedcentral_primary_oai_pubmedcentral_nih_gov_1955446 biomedcentral_primary_oai_biomedcentral_com_1741_7015_5_20 proquest_miscellaneous_68213288 proquest_miscellaneous_20362353 gale_infotracacademiconefile_A168114128 gale_healthsolutions_A168114128 pubmed_primary_17640385 crossref_primary_10_1186_1741_7015_5_20 crossref_citationtrail_10_1186_1741_7015_5_20 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2007-07-19 |
| PublicationDateYYYYMMDD | 2007-07-19 |
| PublicationDate_xml | – month: 07 year: 2007 text: 2007-07-19 day: 19 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC medicine |
| PublicationTitleAlternate | BMC Med |
| PublicationYear | 2007 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | C Qiu (121_CR8) 2005; 4 MW Smith (121_CR20) 2003; 60 DB Hunninghake (121_CR29) 2003; 25 L Sironi (121_CR34) 2005; 25 MH Davidson (121_CR28) 2004; 93 DT Nash (121_CR1) 2006; 97 P Zandi (121_CR17) 2004; 62 LL Krishnan (121_CR26) 2005; 20 S Kinlay (121_CR35) 2003; 108 B Wolozin (121_CR9) 2000; 57 M Simons (121_CR14) 2002; 52 J Shepherd (121_CR18) 2002; 360 P Chan (121_CR39) 1997; 37 AS Khachaturian (121_CR5) 2006; 63 BT Hawkins (121_CR33) 2005; 57 DA Flockhart (121_CR36) 2002; 162 MW Sohn (121_CR21) 2006; 4 MM Breteler (121_CR4) 1994; 308 PS Wang (121_CR41) 2000; 283 A Saheki (121_CR32) 1994; 11 F Forette (121_CR7) 2002; 162 M Cesari (121_CR38) 2004; 6 RS Blumenthal (121_CR24) 2000; 139 RA Deyo (121_CR22) 1992; 45 RE Scranton (121_CR40) 2005; 165 B Wolozin (121_CR43) 2006; 185 M Sjogren (121_CR16) 2006; 127 Z Zhou (121_CR27) 2006; 151 G Griffin (121_CR23) 2005; 71 Group HPSC (121_CR19) 2002; 360 DG Karalis (121_CR30) 2002; 89 MB Bottorff (121_CR37) 2006; 97 K Rockwood (121_CR15) 2002; 59 AB Newman (121_CR3) 2005; 53 TD Rea (121_CR11) 2005; 62 U Gresser (121_CR25) 2004; 9 S Vuletic (121_CR31) 2006; 22 W Marz (121_CR42) 2003; 10 H Jick (121_CR10) 2000; 356 DL Sparks (121_CR12) 2005; 62 I Skoog (121_CR6) 2005; 18 JA Luchsinger (121_CR2) 2005; 65 K Yaffe (121_CR13) 2002; 59 16108925 - J Am Geriatr Soc. 2005 Jul;53(7):1101-7 11890840 - Arch Neurol. 2002 Mar;59(3):378-84 15914466 - Pharmacol Rev. 2005 Jun;57(2):173-85 16116114 - Neurology. 2005 Aug 23;65(4):545-51 1607900 - J Clin Epidemiol. 1992 Jun;45(6):613-9 8165193 - Pharm Res. 1994 Feb;11(2):305-11 16332384 - Mech Ageing Dev. 2006 Feb;127(2):138-47 12457784 - Lancet. 2002 Nov 23;360(9346):1623-30 16581325 - Am J Cardiol. 2006 Apr 17;97(8A):27C-31C 11030795 - Arch Neurol. 2000 Oct;57(10):1439-43 10740137 - Am Heart J. 2000 Apr;139(4):577-83 14766335 - Eur J Med Res. 2004 Jan 26;9(1):1-17 16866913 - Acta Neurol Scand Suppl. 2006;185:63-70 12975259 - Circulation. 2003 Sep 30;108(13):1560-6 15095548 - Med Care Res Rev. 2003 Sep;60(3 Suppl):92S-123S 11089820 - Lancet. 2000 Nov 11;356(9242):1627-31 11863472 - Arch Intern Med. 2002 Feb 25;162(4):405-12 16960448 - Dement Geriatr Cogn Disord. 2006;22(5-6):392-8 15883262 - Arch Neurol. 2005 May;62(5):753-7 12775949 - J Cardiovasc Risk. 2003 Jun;10(3):169-79 16088141 - Dement Geriatr Cogn Disord. 2005;20(4):245-53 15681303 - Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):598-603 16533956 - Arch Neurol. 2006 May;63(5):686-92 15257865 - Curr Hypertens Rep. 2004 Aug;6(4):300-6 12114036 - Lancet. 2002 Jul 6;360(9326):7-22 11843693 - Arch Neurol. 2002 Feb;59(2):223-7 16824220 - Popul Health Metr. 2006 Jul 06;4:7 12374512 - Arch Intern Med. 2002 Oct 14;162(18):2046-52 16616038 - Am J Cardiol. 2006 Apr 15;97(8):1262-5 8025427 - BMJ. 1994 Jun 18;308(6944):1604-8 9208356 - J Clin Pharmacol. 1997 Jun;37(6):496-501 16186471 - Arch Intern Med. 2005 Sep 26;165(17):2007-12 16009757 - Arch Neurol. 2005 Jul;62(7):1047-51 15768617 - Am Fam Physician. 2005 Mar 1;71(5):897-9 16033691 - Lancet Neurol. 2005 Aug;4(8):487-99 15178511 - Am J Cardiol. 2004 Jun 3;93(11A):3C-11C 11897207 - Am J Cardiol. 2002 Mar 15;89(6):667-71 12205648 - Ann Neurol. 2002 Sep;52(3):346-50 16442888 - Am Heart J. 2006 Feb;151(2):273-81 15699299 - Arch Gen Psychiatry. 2005 Feb;62(2):217-24 10866868 - JAMA. 2000 Jun 28;283(24):3211-6 16109319 - Am J Hypertens. 2005 Aug;18(8):1052-9 12860491 - Clin Ther. 2003 Jun;25(6):1670-86 |
| References_xml | – volume: 65 start-page: 545 issue: 4 year: 2005 ident: 121_CR2 publication-title: Neurology doi: 10.1212/01.wnl.0000172914.08967.dc – volume: 360 start-page: 7 issue: 9326 year: 2002 ident: 121_CR19 publication-title: Lancet doi: 10.1016/S0140-6736(02)09327-3 – volume: 162 start-page: 2046 issue: 18 year: 2002 ident: 121_CR7 publication-title: Arch Intern Med doi: 10.1001/archinte.162.18.2046 – volume: 25 start-page: 598 issue: 3 year: 2005 ident: 121_CR34 publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000157145.98200.55 – volume: 185 start-page: 63 year: 2006 ident: 121_CR43 publication-title: Acta Neuropathol Scandanavia doi: 10.1111/j.1600-0404.2006.00687.x – volume: 37 start-page: 496 issue: 6 year: 1997 ident: 121_CR39 publication-title: J Clin Pharmacol doi: 10.1002/j.1552-4604.1997.tb04327.x – volume: 165 start-page: 2007 issue: 17 year: 2005 ident: 121_CR40 publication-title: Arch Intern Med doi: 10.1001/archinte.165.17.2007 – volume: 356 start-page: 1627 issue: 9242 year: 2000 ident: 121_CR10 publication-title: Lancet doi: 10.1016/S0140-6736(00)03155-X – volume: 97 start-page: 27C issue: 8A year: 2006 ident: 121_CR37 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2005.12.007 – volume: 62 start-page: 753 issue: 5 year: 2005 ident: 121_CR12 publication-title: Arch Neurol doi: 10.1001/archneur.62.5.753 – volume: 151 start-page: 273 issue: 2 year: 2006 ident: 121_CR27 publication-title: Am Heart J doi: 10.1016/j.ahj.2005.04.003 – volume: 52 start-page: 346 issue: 3 year: 2002 ident: 121_CR14 publication-title: Ann Neurol doi: 10.1002/ana.10292 – volume: 139 start-page: 577 issue: 4 year: 2000 ident: 121_CR24 publication-title: Am Heart J doi: 10.1016/S0002-8703(00)90033-4 – volume: 10 start-page: 169 issue: 3 year: 2003 ident: 121_CR42 publication-title: J Cardiovasc Risk doi: 10.1097/00043798-200306000-00004 – volume: 4 start-page: 487 issue: 8 year: 2005 ident: 121_CR8 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(05)70141-1 – volume: 59 start-page: 378 issue: 3 year: 2002 ident: 121_CR13 publication-title: Arch Neurol doi: 10.1001/archneur.59.3.378 – volume: 127 start-page: 138 issue: 2 year: 2006 ident: 121_CR16 publication-title: Mech Ageing Dev doi: 10.1016/j.mad.2005.09.020 – volume: 6 start-page: 300 issue: 4 year: 2004 ident: 121_CR38 publication-title: Curr Hypertens Rep doi: 10.1007/s11906-004-0025-5 – volume: 108 start-page: 1560 issue: 13 year: 2003 ident: 121_CR35 publication-title: Circulation doi: 10.1161/01.CIR.0000091404.09558.AF – volume: 360 start-page: 1623 issue: 9346 year: 2002 ident: 121_CR18 publication-title: Lancet doi: 10.1016/S0140-6736(02)11600-X – volume: 4 start-page: 7 year: 2006 ident: 121_CR21 publication-title: Popul Health Metr doi: 10.1186/1478-7954-4-7 – volume: 18 start-page: 1052 issue: 8 year: 2005 ident: 121_CR6 publication-title: Am J Hypertens doi: 10.1016/j.amjhyper.2005.02.013 – volume: 97 start-page: 1262 issue: 8 year: 2006 ident: 121_CR1 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2005.12.031 – volume: 308 start-page: 1604 issue: 6944 year: 1994 ident: 121_CR4 publication-title: Bmj doi: 10.1136/bmj.308.6944.1604 – volume: 22 start-page: 392 issue: 5–6 year: 2006 ident: 121_CR31 publication-title: Dement Geriatr Cogn Disord doi: 10.1159/000095679 – volume: 63 start-page: 686 issue: 5 year: 2006 ident: 121_CR5 publication-title: Arch Neurol doi: 10.1001/archneur.63.5.noc60013 – volume: 45 start-page: 613 issue: 6 year: 1992 ident: 121_CR22 publication-title: J Clin Epidemiol doi: 10.1016/0895-4356(92)90133-8 – volume: 20 start-page: 245 issue: 4 year: 2005 ident: 121_CR26 publication-title: Dement Geriatr Cogn Disord doi: 10.1159/000087345 – volume: 9 start-page: 1 issue: 1 year: 2004 ident: 121_CR25 publication-title: Eur J Med Res – volume: 57 start-page: 173 issue: 2 year: 2005 ident: 121_CR33 publication-title: Pharmacol Rev doi: 10.1124/pr.57.2.4 – volume: 53 start-page: 1101 issue: 7 year: 2005 ident: 121_CR3 publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.2005.53360.x – volume: 283 start-page: 3211 issue: 24 year: 2000 ident: 121_CR41 publication-title: Jama doi: 10.1001/jama.283.24.3211 – volume: 162 start-page: 405 issue: 4 year: 2002 ident: 121_CR36 publication-title: Arch Intern Med doi: 10.1001/archinte.162.4.405 – volume: 59 start-page: 223 issue: 2 year: 2002 ident: 121_CR15 publication-title: Arch Neurol doi: 10.1001/archneur.59.2.223 – volume: 62 start-page: 217 year: 2004 ident: 121_CR17 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.62.2.217 – volume: 25 start-page: 1670 issue: 6 year: 2003 ident: 121_CR29 publication-title: Clin Ther doi: 10.1016/S0149-2918(03)80162-5 – volume: 60 start-page: 92S issue: 3 Suppl year: 2003 ident: 121_CR20 publication-title: Med Care Res Rev doi: 10.1177/1077558703256726 – volume: 71 start-page: 897 issue: 5 year: 2005 ident: 121_CR23 publication-title: Am Fam Physician – volume: 93 start-page: 3C issue: 11A year: 2004 ident: 121_CR28 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2004.02.006 – volume: 11 start-page: 305 issue: 2 year: 1994 ident: 121_CR32 publication-title: Pharm Res doi: 10.1023/A:1018975928974 – volume: 89 start-page: 667 issue: 6 year: 2002 ident: 121_CR30 publication-title: Am J Cardiol doi: 10.1016/S0002-9149(01)02337-2 – volume: 57 start-page: 1439 issue: 10 year: 2000 ident: 121_CR9 publication-title: Arch Neurol doi: 10.1001/archneur.57.10.1439 – volume: 62 start-page: 1047 issue: 7 year: 2005 ident: 121_CR11 publication-title: Arch Neurol doi: 10.1001/archneur.62.7.1047 – reference: 16116114 - Neurology. 2005 Aug 23;65(4):545-51 – reference: 15914466 - Pharmacol Rev. 2005 Jun;57(2):173-85 – reference: 16033691 - Lancet Neurol. 2005 Aug;4(8):487-99 – reference: 16960448 - Dement Geriatr Cogn Disord. 2006;22(5-6):392-8 – reference: 16581325 - Am J Cardiol. 2006 Apr 17;97(8A):27C-31C – reference: 9208356 - J Clin Pharmacol. 1997 Jun;37(6):496-501 – reference: 16616038 - Am J Cardiol. 2006 Apr 15;97(8):1262-5 – reference: 11843693 - Arch Neurol. 2002 Feb;59(2):223-7 – reference: 12775949 - J Cardiovasc Risk. 2003 Jun;10(3):169-79 – reference: 11890840 - Arch Neurol. 2002 Mar;59(3):378-84 – reference: 15095548 - Med Care Res Rev. 2003 Sep;60(3 Suppl):92S-123S – reference: 10740137 - Am Heart J. 2000 Apr;139(4):577-83 – reference: 15178511 - Am J Cardiol. 2004 Jun 3;93(11A):3C-11C – reference: 15768617 - Am Fam Physician. 2005 Mar 1;71(5):897-9 – reference: 12374512 - Arch Intern Med. 2002 Oct 14;162(18):2046-52 – reference: 15681303 - Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):598-603 – reference: 12114036 - Lancet. 2002 Jul 6;360(9326):7-22 – reference: 15257865 - Curr Hypertens Rep. 2004 Aug;6(4):300-6 – reference: 14766335 - Eur J Med Res. 2004 Jan 26;9(1):1-17 – reference: 8025427 - BMJ. 1994 Jun 18;308(6944):1604-8 – reference: 16442888 - Am Heart J. 2006 Feb;151(2):273-81 – reference: 15699299 - Arch Gen Psychiatry. 2005 Feb;62(2):217-24 – reference: 11089820 - Lancet. 2000 Nov 11;356(9242):1627-31 – reference: 11030795 - Arch Neurol. 2000 Oct;57(10):1439-43 – reference: 11863472 - Arch Intern Med. 2002 Feb 25;162(4):405-12 – reference: 16088141 - Dement Geriatr Cogn Disord. 2005;20(4):245-53 – reference: 16824220 - Popul Health Metr. 2006 Jul 06;4:7 – reference: 16108925 - J Am Geriatr Soc. 2005 Jul;53(7):1101-7 – reference: 12205648 - Ann Neurol. 2002 Sep;52(3):346-50 – reference: 16009757 - Arch Neurol. 2005 Jul;62(7):1047-51 – reference: 16109319 - Am J Hypertens. 2005 Aug;18(8):1052-9 – reference: 1607900 - J Clin Epidemiol. 1992 Jun;45(6):613-9 – reference: 11897207 - Am J Cardiol. 2002 Mar 15;89(6):667-71 – reference: 12457784 - Lancet. 2002 Nov 23;360(9346):1623-30 – reference: 10866868 - JAMA. 2000 Jun 28;283(24):3211-6 – reference: 16866913 - Acta Neurol Scand Suppl. 2006;185:63-70 – reference: 16186471 - Arch Intern Med. 2005 Sep 26;165(17):2007-12 – reference: 12975259 - Circulation. 2003 Sep 30;108(13):1560-6 – reference: 8165193 - Pharm Res. 1994 Feb;11(2):305-11 – reference: 16533956 - Arch Neurol. 2006 May;63(5):686-92 – reference: 15883262 - Arch Neurol. 2005 May;62(5):753-7 – reference: 12860491 - Clin Ther. 2003 Jun;25(6):1670-86 – reference: 16332384 - Mech Ageing Dev. 2006 Feb;127(2):138-47 |
| SSID | ssj0025774 |
| Score | 2.3629317 |
| Snippet | Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients... Background Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can... BACKGROUND: Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can... Abstract Background Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins... |
| SourceID | doaj pubmedcentral biomedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 20 |
| SubjectTerms | Age Factors Aged Aged, 80 and over Atorvastatin Calcium Databases as Topic - statistics & numerical data Dementia Dementia - epidemiology Dementia - prevention & control Dosage and administration Drug therapy Female Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Incidence Lovastatin - therapeutic use Male Parkinson Disease - epidemiology Parkinson Disease - prevention & control Parkinson's disease Proportional Hazards Models Pyrroles - therapeutic use Simvastatin Simvastatin - therapeutic use United States - epidemiology Veterans - statistics & numerical data |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9swDBaGHoZdhnXP7FUdBvQk1Lae7q0bVhQDusvWoTeBkmXMQOcUTbrfP1J2sghFsctOQWwmlkhKJEXzI2MfNCQZTZeEhCYIFRorWhVBKIi9dcY4a6lQ-PyrObtQXy715U6rL3onbIIHnhh3JLVLuupS5bqocLsNaDI7HWs0ZQG5kF2jqq02wdQcammb8ZfR3a6FRYs3wzXWzhxtrwktqMt3Ued-VZinjOJ_d6_eMVbli5Q7lun0CXs8u5T8ZJrKPnuQxqfs4fmcNH_Gfnwbfv0GqhwaRj6sOMwSSR2nU1gO_IbwW_ErnbvnHqN82fMuHxwOwGHsOBVH5zqxwxWfczrP2cXp5--fzsTcTkEEtNlrkUD2dR1lHyugPlL44SCZoCTUQYOBvu8bA5XCCKPtwNkU0L2KSaaWcodJvmB743JMrxjXESMZCThxF5TWtq1k7BXYyib8XWcW7Ljgqr-eoDM8gVmXd3BdeRKJJ5F47ZtqwcRGBD7OQOXUL-PK54DFmTv0h1v6zXPuo_xIEi1Gky-gwvlZ4fy_FG7BDkgf_FSnut0g_EltHAaXaO9xQJmCtggceIS50gF5R2BbBeXBRqk8LmvK1cCYlrcrT_nhRmp5P4VxTS0bh__xclLCv5O3RlHCd8FsoZ7FvMs74_AzQ4vXLbqXyrz-H4x6wx5tDsLr9i3bW9_cpnfowa3D-7xY_wDm5URj priority: 102 providerName: Directory of Open Access Journals |
| Title | Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/17640385 https://www.proquest.com/docview/20362353 https://www.proquest.com/docview/68213288 http://dx.doi.org/10.1186/1741-7015-5-20 https://pubmed.ncbi.nlm.nih.gov/PMC1955446 https://doaj.org/article/358e50de08dc4036b658d5c1081beada |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR1da9RAcNEK4ov47fnR7oPQp2iS_Ywg0oqlCOeDelJ8WSabTQ2cOb27iv57Z_b2ro1n8SUhySTZ3ZnJfGVmGHumIAivm5AJKOtM1qXJKukhk-BbY7W2xlCi8Pi9Pp7Idyfq5Pz_p7SAi3-adtRPajKfPv_14_drZPhXkeGtfoFKdZEZlGuZQqRfZddQKmkyxMZyE1FAyjQyFW3cvuevbPfpQEjFWv7bX-wLImv4O-UF-XR0i91MiiU_WFHCbXYl9HfY9XEKnd9lnz92334C5Q91Pe8WHBJeQsPJF8uBz6mKKx6S9z12GuWzljfRfdgBh77hlCIds8X2FzxFdu6xydHbT2-Os9RUIatRci-zAKItCi9anwN1k8KdhaBrKaCoFWho27bUkEu0M6oGrAk1Klk-iFBRBDGI-2ynn_XhIePKoz0jACdua6mUqXLhWwkmNwHva_SIvRysqvu-KqDhqKT18ApylyOUOEKJU67MRyxbo8D5VK6cumZMXTRbrN6C39_Ar99zGeQhYXQwmnhiNj91iV-dUDaovAm5bbxEKV-jptYoX6AGVSPzwYjtET24Vbbq5jPhDgpt0cREqY8DihBEujhwDynfAdeOSm4NIPfWROWQuSliA32YnS0cRYlLocTlENqWhSgtPuPBigjPJ2-0pLDviJkBeQ7mPbzSd19jgfGiQiVT6kf_HddjdmPt6y6qJ2xnOT8LT1FJW9a70bmxG3kQtx8Ov_wBkN0_Yw |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Simvastatin+is+associated+with+a+reduced+incidence+of+dementia+and+Parkinson%27s+disease&rft.jtitle=BMC+medicine&rft.au=Wolozin%2C+Benjamin&rft.au=Wang%2C+Stanley+W&rft.au=Li%2C+Nien-Chen&rft.au=Lee%2C+Austin&rft.date=2007-07-19&rft.eissn=1741-7015&rft.volume=5&rft.spage=20&rft.epage=20&rft_id=info:doi/10.1186%2F1741-7015-5-20&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |